In a filing, Abbott Laboratories revealed its EXECUTIVE VICE PRESIDENT Salvadori Daniel Gesua Sive unloaded Company’s shares for reported $0.11 million on Mar 01 ’24. In the deal valued at $118.50 per share,963 shares were sold. As a result of this transaction, Salvadori Daniel Gesua Sive now holds 125,697 shares worth roughly $13.69 million.
Then, ALLEN HUBERT L sold 853 shares, generating $101,080 in total proceeds. Upon selling the shares at $118.50, the EXECUTIVE VICE PRESIDENT now owns 184,806 shares.
Before that, Morrone Louis H. sold 801 shares. Abbott Laboratories shares valued at $94,918 were divested by the EXECUTIVE VICE PRESIDENT at a price of $118.50 per share. As a result of the transaction, Morrone Louis H. now holds 62,968 shares, worth roughly $6.86 million.
Wolfe Research upgraded its Abbott Laboratories [ABT] rating to a Peer perform from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who decreased its forecast for the stock in late May from “an Overweight” to “an Equal-weight”. Wolfe Research also remained covering ABT and reiterated its “an Underperform” recommendation on April 20, 2023. UBS maintained its rating on April 20, 2023. It rated ABT as “a Buy”.
Price Performance Review of ABT
On Monday, Abbott Laboratories [NYSE:ABT] saw its stock fall -0.20% to $108.89. Over the last five days, the stock has lost -1.47%. Abbott Laboratories shares have fallen nearly -1.07% since the year began. Nevertheless, the stocks have risen 5.10% over the past one year. While a 52-week high of $121.64 was reached on 03/08/24, a 52-week low of $89.67 was recorded on 04/12/24. SMA at 50 days reached $114.61, while 200 days put it at $106.71. A total of 4.59 million shares were traded, compared to the trading of 4.04 million shares in the previous session.
Levels Of Support And Resistance For ABT Stock
The 24-hour chart illustrates a support level at 108.18, which if violated will result in even more drops to 107.48. On the upside, there is a resistance level at 110.24. A further resistance level may holdings at 111.60. The Relative Strength Index (RSI) on the 14-day chart is 36.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.79%. Stochastics %K at 22.02% indicates the stock is a holding.
The most recent change occurred on April 20, 2023 when Raymond James resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $123.
